▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1087 by analyst upside · 2026-09-28
PHVS
Pharvaris N.V.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+80.7%
implied upside to consensus target
Current Price $32.02
Consensus Target $57.85
Bull Target $77.29
Bear Target $41.67
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
1
Sell
0
52-Week Low $20.65
52-Week High $43.25
YTD Return +20.9%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.96
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $20.65
52-Week High $43.25
Current Price $32.02
Bear Target $41.67
Bull Target $77.29
● Now $32.02 ● Target $57.85
TRADING DATA
Avg Volume 744K
YTD Return +20.9%
Analyst Count 14
Consensus Buy
Upside to Target +80.7%
Last Updated 2026-09-28

ANALYST SUMMARY

Pharvaris N.V. (PHVS) is currently trading at $32.02 with a Wall Street consensus price target of $57.85, implying potential upside of 80.7% over the next 12 months. 14 analysts currently cover PHVS, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $77.29, while the most cautious has a target of $41.67.

PHVS operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 20.9% year-to-date and is currently trading near the upper end of its 52-week range of $20.65 – $43.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ADMA +81.2%
ADMA Biologics, Inc.
$2B · P/E 13.4x · Buy
PBH +45.5%
Prestige Consumer Healthcare Inc.
$2B · P/E 13.1x · Buy
GTBIF +106.5%
Green Thumb Industries Inc.
$2B · P/E 14.4x · Buy
INVA +68.8%
Innoviva, Inc.
$1B · P/E 4.8x · Buy
ANIP +42.9%
ANI Pharmaceuticals, Inc.
$2B · P/E 16.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PHVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-09-10 62% win rate (8 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-09-09 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-09-09 29% win rate (7 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-09-09 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-09-09 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-09-09 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-09-09 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-09-08 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
21/30
Consensus clarity
8/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →